Adnavance Technologies Inc., a Vancouver-based developer of direct detection molecular diagnostic tests for medical applications, has raised Cnd$3.7 million in Series B funding. GrowthWorks Capital led the round, and was joined by JovInvestment Management and the Business Development Bank of
In other Adnavance news, the company has named Randy White as CEO. His former CEO roles have been with Nanogen (Nasdaq: NGEN) and Xenomics (OTC BB: XNOM).
PRESS RELEASE
Adnavance Technologies Inc., a developer of new direct detection molecular diagnostic tests for medical applications, announced today that it completed a Series B financing totaling $3.7 million CAD. The proceeds will fund continued development and expansion of the Company's ultra-sensitive proprietary metalized-DNA (M-DNA
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.